Kezdőlap・Részvénylista・Moderna Inc

Moderna Inc

Lezárt

SzektorEgészségügy

56.94 3.32

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

55.11

Maximum

58.19

Fő mutatók
By Trading Economics
Bevétel	561M -782M
Értékesítés	-244M 145M
Egy részvényre jutó nyereség	-1.97
Profit margin	-539.31
Munkavállalók	4,700
EBITDA	554M -704M

Ajánlások
By TipRanks
Ajánlások	Semleges
12 hónapos előrejelzés	-11.28% downside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 5.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-194M 22B
Előző nyitás	53.62
Előző zárás	56.94

Hangulat hírek alapján

By Acuity

29%

71%

110 / 340 Rangsor szerint Healthcare

Moderna Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 4. 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

2026. aug. 3. 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

2026. júl. 31. 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

2026. júl. 30. 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

2026. júl. 29. 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

2026. júl. 28. 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

2026. júl. 27. 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

2026. júl. 24. 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

2026. júl. 23. 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

2026. júl. 21. 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

2026. júl. 20. 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Társak összehasonlítása

Árváltozás

Moderna Inc Előrejelzés

Célár

By TipRanks

-11.28% elmozdulás lefelé

12 hónapos előrejelzés

Átlag 48.92 USD -11.28%

Magas 77 USD

Alacsony 39 USD

15 Wall Street elemző 12 hónapos célárain alapulva a(z)Moderna Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Semleges

15 ratings

Vétel

Tartás

Eladás

15 Wall Street elemző célárain alapulva a(z)Moderna Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

110 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.